Clinical efficacy and safety of Panax notoginseng saponins in treating chronic obstructive pulmonary disease with blood hypercoagulability: A meta-analysis of randomized controlled trials.

Ruiling Zhou, Jie Zhang, Wen Zhang, Xinyu Zhang, Haiyan Zhang, Xia Shi, Bing Wang, Qiong Zhang, He Zhang

Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology 2024;125():155244

PMID: 38216446

Abstract

BACKGROUND

Panax notoginseng saponins (PNS) are the primary active components of an ancient Chinese herb Panax notoginseng. Hypercoagulable state of blood (HCS) is an independent risk factor and a cause of death in chronic obstructive pulmonary disease (COPD). Several vivo studies have demonstrated the use of PNS preparations for treating COPD with HCS.

PURPOSE

This study aimed to systematically evaluate the clinical efficacy and safety of PNS preparations in treating COPD with HCS.

STUDY DESIGN

Meta-analysis of the randomized controlled trials (RCTs) was conducted to review data.

METHODS

RCTs on the treatment of COPD with HCS and PNS preparations were searched from PubMed, Cochrane Library, Embase, Web of Science, Chinese National Knowledge Infrastructure, Vip Information Database, Wanfang data, and Chinese Biomedical Literature Database. Relevant data were extracted from the included studies and methodological quality evaluation was performed. R language (version 4.2.3) was applied for the meta-analysis.

RESULTS

Twenty RCTs involving 1831 patients were analyzed. The results revealed that PNS preparations considerably increased the total clinical efficiency, improved forced expiratory volume in one second percent of predicted, and forced expiratory volume/forced vital capacity ratio. Further, PNS preparations improved fibrinogen, plasma d-dimer, whole blood viscosity at high cut, whole blood viscosity at low cut, and plasma viscosity levels. The results obtained for activated partial thromboplastin and prothrombin times were not statistically significant. Finally, PNS preparations increased partial pressure of oxygen and decreased carbon dioxide pressure.

CONCLUSION

This is the first relatively comprehensive systematic review of the clinical efficacy and safety of PNS preparations for treating COPD with HCS. The study revealed that PNS preparations considerably improve lung function, hypoxia, and blood hypercoagulability in patients with COPD and HCS without increasing the risk of hemorrhage and has a good safety profile; therefore, it can be used as a new modulating agent and anticoagulant.

Copyright © 2023. Published by Elsevier GmbH.

Address: Beijing University of Chinese medicine, Beijing 100029, China; Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.; Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.; Beijing University of Chinese medicine, Beijing 100029, China.; Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China. Electronic address: [email protected].; Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China. Electronic address: [email protected].

Link outs

Free resources

Subscription / membership required

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.